The Effect of Therapy Regimen on Antitumor Efficacy of the Nanosomal Doxorubicin against Rat Glioblastoma 101.8-Reference-Cited by-同舟云学术

The Effect of Therapy Regimen on Antitumor Efficacy of the Nanosomal Doxorubicin against Rat Glioblastoma 101.8

Published:2024-03 Issue:5 Volume:176 Page:697-702
ISSN:0007-4888
Container-title:Bulletin of Experimental Biology and Medicine
language:en
Short-container-title:Bull Exp Biol Med

Author:

Alekseeva A. I.,Khalansky A. S.,Miroshnichenko E. A.,Gerasimov A. D.,Sentyabreva A. V.,Kudelkina V. V.,Osipova N. S.,Gulyaev M. V.,Gelperina S. E.,Kosyreva A. M.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10517-024-06092-1.pdf

Reference20 articles.

1. Delgado-López PD, Corrales-García EM. Survival in glioblastoma: a review on the impact of treatment modalities. Clin. Transl. Oncol. 2016;18(11):1062-1071. doi: https://doi.org/10.1007/s12094-016-1497-x

2. Pereverzeva E, Treschalin I, Treschalin M, Arantseva D, Ermolenko Y, Kumskova N, Maksimenko O, Balabanyan V, Kreuter J, Gelperina S. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. Int. J. Pharm. 2019;554:161-178. doi: https://doi.org/10.1016/j.ijpharm.2018.11.014

3. Kudelkina VV, Khalansky AS, Makarova OV, Tsvetkov IS, Kosyreva AM, Alekseeva AI, Shelkov AY, Maksimenko OO, Razzhivina VA, Gelperina SE. Comparative morphological and biochemical characteristics of the toxic effects of doxorubicin and nanosomal PLGA-doxorubicin form in the experimental glioblastoma treatment. Klin. Eksper. Morfol. 2021;10(1):58-65. Russian. doi: https://doi.org/10.31088/CEM2021.10.1.58-65

4. Wen J, Chen W, Zhu Y, Zhang P. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis. BMC Cancer. 2021;21(1):81. doi: https://doi.org/10.1186/s12885-021-07800-0.

5. Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. Neuro Oncol. 2020;22(5):601-612. doi: https://doi.org/10.1093/neuonc/noaa015